Neoadjuvant chemotherapy in geriatric head and neck cancers.

Neoadjuvant chemotherapy in geriatric head and neck cancers.

Head Neck. 2017 Mar 01;:

Authors: Patil VM, Noronha V, Joshi A, Ramaswamy A, Dhumal S, Juvekar S, Arya S, Mahajan A, Chaturvedi P, D'Cruz A, Bhattacharjee A, Prabhash K

Abstract
BACKGROUND: The purpose of this study was to present our findings on the treatment completion rates and outcomes in geriatric patients with head and neck cancer treated with neoadjuvant chemotherapy followed by definitive therapy.
METHODS: Geriatric patients with locally advanced head and neck cancer who received neoadjuvant chemotherapy were selected for this analysis. Overall survival (OS) and progression-free survival (PFS) were estimated.
RESULTS: Forty-six of 49 patients completed neoadjuvant chemotherapy (93.9%). The compliance to local treatment was 73.3% and the median OS was 49.9 months (95% confidence interval [CI] = 22.0-77.8 months) in patients who received neoadjuvant chemotherapy for organ preservation (n = 15). In patients receiving neoadjuvant chemotherapy for technically unresectable disease, the corresponding figures were 82.06% and 9.0 months (95% CI = 5.9-12.1 months), respectively.
CONCLUSION: Individualized neoadjuvant chemotherapy protocols in geriatric patients have high compliance rates to treatment and the median OS in geriatric patients treated for organ preservation is similar to that of young patients. © 2017 Wiley Periodicals, Inc. Head Neck, 2017.

PMID: 28248432 [PubMed - as supplied by publisher]

http://ift.tt/2lX4sle